Serina Therapeutics (FRA:2BO) EBIT: €-17.97 Mil (TTM As of Mar. 2026)


FRA:2BO Serina Therapeutics Inc FRA:2BO
19 GF Score
Price €1.48
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics EBIT?

Serina Therapeutics FRA:2BO +8.03% 19 EBIT is €-17.97 Mil as of Mar. 2026. GuruFocus rates FRA:2BO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Serina Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-5.80 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-17.97 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Serina Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -868.43%. Serina Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -3,286.75%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Serina Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -155.85%.

Serina Therapeutics  (FRA:2BO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Serina Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-21.728 * ( 1 - 0% )/( (1.801 + 3.203)/ 2 )
=-21.728/2.502
=-868.43 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.936 - 1.986 - ( 4.08 - max(0, 3.043 - 5.192+4.08))
=1.801

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=23.614 - 2.995 - ( 21.215 - max(0, 5.484 - 22.9+21.215))
=3.203

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Serina Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-23.188/( ( (0.719 + max(-1.931, 0)) + (0.692 + max(-3.799, 0)) )/ 2 )
=-23.188/( ( 0.719 + 0.692 )/ 2 )
=-23.188/0.7055
=-3,286.75 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.112) - (1.986 + 0 + 1.057)
=-1.931

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.685) - (2.995 + 0 + 2.489)
=-3.799

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Serina Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-17.966/11.528
=-155.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics EBIT Related Terms

Serina Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics EBIT Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
-1.12 -2.52 5.34 -10.20 -16.21

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.46 -5.60 -3.91 -2.66 -5.80

FRA:2BO vs NRSN, IGC, PVCT: EBIT Comparison

For the Biotechnology subindustry, Serina Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Serina Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's EV-to-EBIT falls into.


FRA:2BO
19GF Score
Serina Therapeutics Inc FRA:2BO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-17.97 Mil mean?
Serina Therapeutics (FRA:2BO) has a EBIT of €-17.97 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Serina Therapeutics.
Is Serina Therapeutics' EBIT too high?
Serina Therapeutics' current EBIT is €-17.97 Mil. Overall, Serina Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' EBIT compare to NRSN and IGC?
Serina Therapeutics' EBIT of €-17.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Serina Therapeutics. Serina Therapeutics's current EBIT is €-17.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (FRA:2BO) has a current EBIT of €-17.97 Mil. The current EBIT is €-17.97 Mil. Serina Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Serina Therapeutics (FRA:2BO), the current EBIT is €-17.97 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges SER:USA
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
19GF Score

Get the complete analysis for FRA:2BO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.48
Price